MyFinsight
Home
Blog
About
Maturities/(purchase) of short-term
investments, net of...
-$6,963,830
Proceeds from the sale of
assets, net of sales...
$178,200
(99.41%↑ Y/Y)
Net cash provided by
(used in) investing...
$7,142,030
(128.96%↑ Y/Y)
Net increase
(decrease) in cash and cash...
-$80,658
(99.82%↑ Y/Y)
Canceled cashflow
$7,142,030
Change in estimate for
legal contingency
$3,250,000
Stock-based compensation
expense
$1,271,210
(-69.98%↓ Y/Y)
Prepaid expenses
-$808,370
(-176.13%↓ Y/Y)
Loss from disposal of
assets
-$589,660
Accrued payroll
liabilities
$456,174
(285.26%↑ Y/Y)
Accounts payable
$341,471
(-86.79%↓ Y/Y)
Depreciation and
amortization
$157,598
(-56.76%↓ Y/Y)
Other assets
-$27,600
Right-of-use assets
$1
Purchase under employee
stock purchase plan
$6,274
(-65.45%↓ Y/Y)
Net cash used in
operating activities
-$7,121,674
(64.27%↑ Y/Y)
Canceled cashflow
$6,902,084
Net cash (used in)
provided by in financing...
-$101,014
(-656.31%↓ Y/Y)
Canceled cashflow
$6,274
Net loss
-$10,786,594
(62.45%↑ Y/Y)
Other current
liabilities
-$2,788,903
(-271.95%↓ Y/Y)
Other current assets
$244,777
(116.58%↑ Y/Y)
Gains from asset sales
$178,200
(99.41%↑ Y/Y)
Operating lease liability
-$25,284
(71.28%↑ Y/Y)
Repayment of insurance
premium loan payable
$107,288
Back
Back
Cash Flow
Skye Bioscience, Inc. (SKYE)
Skye Bioscience, Inc. (SKYE)
source: myfinsight.com